Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Allergic Rhinitis Treatment Pipeline Review H2 2016

Friday, October 14, 2016 4:27
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Allergic Rhinitis – Pipeline Review, H2 2016’, provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685907-allergic-rhinitis-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis 
- The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects 
- The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685907-allergic-rhinitis-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Allergic Rhinitis Overview 9 
Therapeutics Development 10 
Pipeline Products for Allergic Rhinitis – Overview 10 
Pipeline Products for Allergic Rhinitis – Comparative Analysis 11 
Allergic Rhinitis – Therapeutics under Development by Companies 12 
Allergic Rhinitis – Therapeutics under Investigation by Universities/Institutes 16 
Allergic Rhinitis – Pipeline Products Glance 17 
Late Stage Products 17 
Clinical Stage Products 18 
Early Stage Products 19 
Allergic Rhinitis – Products under Development by Companies 20 
Allergic Rhinitis – Products under Investigation by Universities/Institutes 25 
Allergic Rhinitis – Companies Involved in Therapeutics Development 26 
3M Drug Delivery Systems 26 
Accolade Pharmaceuticals, LLC 27 
AFFiRiS AG 28 
ALK-Abello A/S 29 
Allergy Therapeutics Plc 30 
Ampio Pharmaceuticals, Inc. 31 
Array BioPharma Inc. 32 
ASIT biotech s.a. 33 
Axikin Pharmaceuticals, Inc. 34 
Chong Kun Dang Pharmaceutical Corp. 35 
Chrysalis BioTherapeutics, Inc. 36 
ELORAC, Inc. 37 
Faes Farma, S.A. 38 
Fountain Biopharma Inc. 39 
GlaxoSmithKline Plc 40 
Glenmark Pharmaceuticals Ltd. 41 
HAL Allergy BV 42 
Hisamitsu Pharmaceutical Co., Inc. 43 
Johnson & Johnson 44 
Laboratorios LETI S.L. 45 
Ligand Pharmaceuticals, Inc. 46 
Marinomed Biotechnologie GmbH 47 
Merck & Co., Inc. 48 
Panmira Pharmaceuticals, LLC. 49 
Paradigm Biopharmaceuticals Limited 50 
Pfizer Inc. 51 
Protectimmun GmbH 52 
Roxall Medizin GmbH 53 
Sanofi 54 
Shionogi & Co., Ltd. 55 
Stallergenes Greer plc 56 
Sun Pharma Advanced Research Company Ltd. 57 
Taiho Pharmaceutical Co., Ltd. 58 
VentiRx Pharmaceuticals, Inc. 59 
Xencor, Inc. 60 
Allergic Rhinitis – Therapeutics Assessment 61 
Assessment by Monotherapy Products 61 
Assessment by Combination Products 62 
Assessment by Target 63 
Assessment by Mechanism of Action 65 
Assessment by Route of Administration 67 
Assessment by Molecule Type 69 
Drug Profiles 71 
(azelastine hydrochloride + budesonide) – Drug Profile 71 
(fexofenadine hydrochloride + phenylephrine hydrochloride) – Drug Profile 72 
(levocabastine hydrochloride + mometasone furoate) – Drug Profile 73 
854-A – Drug Profile 74 
Allergen for Allergic Asthma and Allergic Rhinitis – Drug Profile 75 
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis – Drug Profile 76 
Allergen for Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 77 
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma – Drug Profile 78 
Allergen for Asthma and Perennial Allergic Rhinitis – Drug Profile 79 
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 80 
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 81 
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 82 
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 83 
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis – Drug Profile 84 
AM-211 – Drug Profile 85 
AM-461 – Drug Profile 86 
Ampion – Drug Profile 87 
AR-460770 – Drug Profile 95 
Arabinogalactan – Drug Profile 96 
asapiprant – Drug Profile 97 
B-244 – Drug Profile 98 
beta-escin – Drug Profile 99 
bilastine – Drug Profile 100 
budesonide – Drug Profile 102 
CBP-174 – Drug Profile 103 
cidoxepin hydrochloride – Drug Profile 104 
clustoid wiesenlieschgras – Drug Profile 105 
desloratadine – Drug Profile 106 
emedastine difumarate – Drug Profile 108 
esketamine hydrochloride – Drug Profile 109 
FB-825 – Drug Profile 112 
gp-ASIT – Drug Profile 113 
GSK-2245035 – Drug Profile 115 
GSP-301 – Drug Profile 117 
Lactococcus lactis G121 – Drug Profile 118 
motolimod – Drug Profile 119 
nasapaque – Drug Profile 122 
pentosan polysulfate sodium – Drug Profile 123 
PF-06444752 – Drug Profile 125 
PF-06444753 – Drug Profile 127 
Pollinex Quattro Tree – Drug Profile 129 
rE58 – Drug Profile 131 
Small Molecule for Allergic Rhinitis – Drug Profile 132 
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases – Drug Profile 133 
Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders – Drug Profile 134 
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis – Drug Profile 135 
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis – Drug Profile 136 
STAGR-120 – Drug Profile 137 
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract – Drug Profile 138 
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine – Drug Profile 140 
SUN-0597 – Drug Profile 145 
TAS-205 – Drug Profile 147 
Vaccine to Target IgE for Allergic Rhinitis and Asthma – Drug Profile 148 
VTX-1463 – Drug Profile 149 
XmAb-7195 – Drug Profile 150 
Zafi-3 – Drug Profile 151 
Allergic Rhinitis – Dormant Projects 152 
Allergic Rhinitis – Discontinued Products 162 
Allergic Rhinitis – Product Development Milestones 165 
Featured News & Press Releases 165 
Appendix 174 
Methodology 174 
Coverage 174 
Secondary Research 174 
Primary Research 174 
Expert Panel Validation 174 
Contact Us 174 
Disclaimer 175

List of Tables 
Number of Products under Development for Allergic Rhinitis, H2 2016 15 
Number of Products under Development for Allergic Rhinitis – Comparative Analysis, H2 2016 16 
Number of Products under Development by Companies, H2 2016 17 
Number of Products under Development by Companies, H2 2016 (Contd..1) 18 
Number of Products under Development by Companies, H2 2016 (Contd..2) 19 
Number of Products under Investigation by Universities/Institutes, H2 2016 20 
Comparative Analysis by Late Stage Development, H2 2016 21 
Comparative Analysis by Clinical Stage Development, H2 2016 22 
Comparative Analysis by Early Stage Development, H2 2016 23 
Products under Development by Companies, H2 2016 24 
Products under Development by Companies, H2 2016 (Contd..1) 25 
Products under Development by Companies, H2 2016 (Contd..2) 26 
Products under Development by Companies, H2 2016 (Contd..3) 27 
Products under Development by Companies, H2 2016 (Contd..4) 28 
Products under Investigation by Universities/Institutes, H2 2016 29 
Allergic Rhinitis – Pipeline by 3M Drug Delivery Systems, H2 2016 30 
Allergic Rhinitis – Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 31 
Allergic Rhinitis – Pipeline by AFFiRiS AG, H2 2016 32 
Allergic Rhinitis – Pipeline by ALK-Abello A/S, H2 2016 33 
Allergic Rhinitis – Pipeline by Allergy Therapeutics Plc, H2 2016 34 
Allergic Rhinitis – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 35 
Allergic Rhinitis – Pipeline by Array BioPharma Inc., H2 2016 36 
Allergic Rhinitis – Pipeline by ASIT biotech s.a., H2 2016 37 
Allergic Rhinitis – Pipeline by Axikin Pharmaceuticals, Inc., H2 2016 38 
Allergic Rhinitis – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 39 
Allergic Rhinitis – Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 40 
Allergic Rhinitis – Pipeline by ELORAC, Inc., H2 2016 41 
Allergic Rhinitis – Pipeline by Faes Farma, S.A., H2 2016 42 
Allergic Rhinitis – Pipeline by Fountain Biopharma Inc., H2 2016 43 
Allergic Rhinitis – Pipeline by GlaxoSmithKline Plc, H2 2016 44 
Allergic Rhinitis – Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 45 
Allergic Rhinitis – Pipeline by HAL Allergy BV, H2 2016 46 
Allergic Rhinitis – Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 47 
Allergic Rhinitis – Pipeline by Johnson & Johnson, H2 2016 48 
Allergic Rhinitis – Pipeline by Laboratorios LETI S.L., H2 2016 49 
Allergic Rhinitis – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 50 
Allergic Rhinitis – Pipeline by Marinomed Biotechnologie GmbH, H2 2016 51 
Allergic Rhinitis – Pipeline by Merck & Co., Inc., H2 2016 52 
Allergic Rhinitis – Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 53 
Allergic Rhinitis – Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 54 
Allergic Rhinitis – Pipeline by Pfizer Inc., H2 2016 55 
Allergic Rhinitis – Pipeline by Protectimmun GmbH, H2 2016 56 
Allergic Rhinitis – Pipeline by Roxall Medizin GmbH, H2 2016 57 
Allergic Rhinitis – Pipeline by Sanofi, H2 2016 58 
Allergic Rhinitis – Pipeline by Shionogi & Co., Ltd., H2 2016 59 
Allergic Rhinitis – Pipeline by Stallergenes Greer plc, H2 2016 60 
Allergic Rhinitis – Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 61 
Allergic Rhinitis – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 62 
Allergic Rhinitis – Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 63 
Allergic Rhinitis – Pipeline by Xencor, Inc., H2 2016 64 
Assessment by Monotherapy Products, H2 2016 65 
Assessment by Combination Products, H2 2016 66 
Number of Products by Stage and Target, H2 2016 68 
Number of Products by Stage and Mechanism of Action, H2 2016 70 
Number of Products by Stage and Route of Administration, H2 2016 72 
Number of Products by Stage and Molecule Type, H2 2016 74 
Allergic Rhinitis – Dormant Projects, H2 2016 156 
Allergic Rhinitis – Dormant Projects (Contd..1), H2 2016 157 
Allergic Rhinitis – Dormant Projects (Contd..2), H2 2016 158 
Allergic Rhinitis – Dormant Projects (Contd..3), H2 2016 159 
Allergic Rhinitis – Dormant Projects (Contd..4), H2 2016 160 
Allergic Rhinitis – Dormant Projects (Contd..5), H2 2016 161 
Allergic Rhinitis – Dormant Projects (Contd..6), H2 2016 162 
Allergic Rhinitis – Dormant Projects (Contd..7), H2 2016 163 
Allergic Rhinitis – Dormant Projects (Contd..8), H2 2016 164 
Allergic Rhinitis – Dormant Projects (Contd..9), H2 2016 165 
Allergic Rhinitis – Discontinued Products, H2 2016 166 
Allergic Rhinitis – Discontinued Products (Contd..1), H2 2016 167 
Allergic Rhinitis – Discontinued Products (Contd..2), H2 2016 168

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685907

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.